Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -0.05.EBIT: As of FY2025 Q3, the actual value is USD -675.31 K.<h3>Segment Revenue</h3><ul><li>The company did not generate any revenue for the three and nine months ended September 30, 2025, and 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended September 30, 2025, the net loss was $2,895,585 compared to $2,959,426 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $9,222,798 compared to $4,083,109 for the same period in 2024.</li><li>Operating Expenses: For the three months ended September 30, 2025, operating expenses were $1,853,304 compared to $2,870,932 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $5,333,124 compared to $3,688,584 for the same period in 2024.</li><li>Interest Expense: For the three months ended September 30, 2025, interest expense was $1,177,999 compared to $44,956 for the same period in 2024. For the nine months ended September 30, 2025, interest expense was $3,491,961 compared to $60,020 for the same period in 2024.</li><li>Share-based Compensation: For the three months ended September 30, 2025, share-based compensation was $639,586 compared to $1,952,852 for the same period in 2024. For the nine months ended September 30, 2025, share-based compensation was $1,525,281 compared to $1,990,366 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $4,610,390 compared to $2,002,358 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the nine months ended September 30, 2025, net cash used in investing activities was $0 compared to $123,497 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $11,894,683 compared to $2,173,942 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Licenses and Patents: The company acquired various licenses and patents, including a Non-Exclusive License Agreement, various generic drugs, four generic drugs (Encore), and a Needleless Syringe License. The total value of intangible assets as of September 30, 2025, was $2,299,554.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue developing essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform, as well as two proprietary, patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform.</li><li>Non-Core Business: The company terminated the Share Exchange Agreement to acquire SB Security Holdings, LLC, an internet-connected video doorbell service company, on June 13, 2025.</li><li>Priority: The company is focused on obtaining additional working capital funding from the sale of equity and/or debt securities to continue executing its development plans and operations. Without additional funding, there is substantial doubt about the company’s ability to continue as a going concern for twelve months from the date of these financial statements.</li></ul>

Klotho Neurosciences - W27 | 10-Q: FY2025 Q3 Revenue: USD 0